Fiche publication
Date publication
avril 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel
,
Dr LEROUX Agnès
Tous les auteurs :
Salas S, Brulard C, Terrier P, Ranchere-Vince D, Mechine-Neuville A, Guillou L, Lae M, Leroux A, Verola O, Kurtz JE, Bonvalot S, Blay JY, Le Cesne A, Aurias A, Coindre JM, Chibon F
Lien Pubmed
Résumé
PURPOSE: Because desmoid tumors (DT) exhibit an unpredictable clinical course, translational research is crucial to identify the predictive factors of progression in addition to the clinical parameters. The main issue is to detect patients who are at a higher risk of progression. The aim of this work was to identify molecular markers that can predict Progression-Free Survival (PFS). EXPERIMENTAL DESIGN: Gene-expression screening was conducted on 115 available independent untreated primary desmoid tumors using cDNA microarray. We established a prognostic gene expression signature composed of 36 genes. To test robustness, we randomly generated 1000 36-gene signatures and compared their outcome association to our define 36-genes molecular signature and we calculated Positive Predictive Value and Negative Predictive Value. RESULTS: Multivariate analysis showed that our molecular signature had a significant impact on PFS while no clinical factor had any prognostic value. Among the 1000 random signatures generated, 56.7% were significant and none was more significant than our 36-gene molecular signature. Positive and negative predictive value was high (75.58% and 81.82% respectively). Finally, the top two genes down-regulated in no-recurrence were FECH and STOML2 and the top gene up-regulated in no-recurrence was TRIP6. CONCLUSIONS: By analyzing expression profiles, we have identified a gene expression signature that is able to predict Progression-Free Survival. This tool may be useful for prospective clinical studies.
Référence
Clin Cancer Res. 2015 Apr 15. pii: clincanres.2910.2014.
